Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Bellicum Pharmaceuticals, Inc. BLCM
$0.74
-$0.06 (-7.50%)
На 18:00, 12 мая 2023
Ранг: 1
Ключевые показатели
-
Marketcap
7056114.00000000
-
week52high
1.77
-
week52low
0.23
-
Revenue
1500000
-
P/E TTM
0
-
Beta
1.56539700
-
EPS
-0.70000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:00
Описание компании
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Ladenburg Thalmann | Buy | 16 февр 2022 г. | |
| Wells Fargo | Outperform | Market Perform | 25 ноя 2020 г. |
| Raymond James | Outperform | Outperform | 25 ноя 2020 г. |
| Citigroup | Buy | Buy | 25 ноя 2020 г. |
| Wells Fargo | Equal-Weight | Overweight | 30 окт 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Stonehouse Jon P | A | 204086 | 121452 | 03 янв 2023 г. |
| Huber Reid M | A | 153179 | 87196 | 03 янв 2023 г. |
| DAVIS STEPHEN | A | 136854 | 74739 | 03 янв 2023 г. |
| Daly James M | A | 109873 | 60414 | 03 янв 2023 г. |
| Klimovsky Judith V | A | 110098 | 60414 | 03 янв 2023 г. |
| Stonehouse Jon P | A | 82634 | 60580 | 01 сент 2022 г. |
| Huber Reid M | A | 65983 | 46489 | 01 сент 2022 г. |
| Daly James M | A | 49459 | 35082 | 01 сент 2022 г. |
| DAVIS STEPHEN | A | 62115 | 43400 | 01 сент 2022 г. |
| Klimovsky Judith V | A | 49684 | 35082 | 01 сент 2022 г. |
Новостная лента
Bellicum (BLCM) Down on Ending Development of CAR-T Candidates
Zacks Investment Research
16 мар 2023 г. в 13:00
Following the decision to discontinue the development of pipeline candidates, Bellicum Pharmaceuticals (BLCM) is left with no candidate in clinical development. The stock is down 50% post the news.
Is Bellicum Pharmaceuticals (BLCM) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
27 февр 2023 г. в 11:17
Here is how Bellicum Pharmaceuticals (BLCM) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium
GlobeNewsWire
19 янв 2023 г. в 07:30
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The meeting is being held February 16-18, 2023 in San Francisco and virtually. The ongoing trial is being conducted in patients with metastatic castration-resistant prostate cancer.
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
01 сент 2022 г. в 07:30
HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will participate in the H.C. Wainwright 24th Annual Global Investment Conference (hybrid). A pre-recorded presentation will be available to view on-demand beginning at 7 a.m. ET / 4 a.m. PT on September 12, 2022, and will remain accessible for 90 days in the Events and Presentations section of the Bellicum website.